Herantis Pharma Announces an Oral Presentation and a Poster Presentation related to First-in-Man CDNF Clinical Trial at AD/PD™ Virtual Conference
Herantis Pharma Plc Company Press Release, 11 March 2021 at 08:00 a.m. EET Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, announced today that the company will be presenting an oral presentation and a poster presentation summarizing the results from the Phase I-II First-In-Man Clinical Trial of CDNF in Parkinson’s Disease at the 15[th] International Conference on Alzheimer’s and Parkinson’s Diseases, AD/PD™ 2021 Virtual Conference, March 9-14, 2021. The oral presentation